The DOI matches its Crossref record.
Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group
Open accessAbstract
The Multicenter Diltiazem Postinfarction Trial (MDPIT) reported no consistent diltiazem effect on new or worsened congestive heart failure (CHF) during 12-52 months' follow-up after acute myocardial infarction. This was puzzling in light of the observation that patients with findings suggesting left ventricular dysfunction (LVD) at baseline on diltiazem had more cardiac events (cardiac mortality or recurrent nonfatal infarction) than such patients on placebo. We hypothesized that diltiazem increased the frequency of late CHF as well as of cardiac events, but only in patients predisposed by LVD. Using the same characterizing variables as the primary MDPIT analysis, we found that patients with pulmonary congestion, anterolateral Q wave infarction, or reduced ejection fraction (EF) at baseline were more likely to have CHF during follow-up than those without these markers of LVD. CHF was particularly frequent in the patients with LVD who were randomized to diltiazem. Among those with a baseline EF of less than 0.40, late CHF appeared in 12% (39/326) receiving placebo and 21% (61/297) receiving diltiazem (p = 0.004). Life table analysis in patients with an EF of less than 0.40 confirmed more frequent late CHF in those taking diltiazem (p = 0.0017). In addition, the diltiazem-associated rise in the frequency of late CHF was progressively greater with increasingly severe decrements in baseline EF. This diltiazem effect was absent in patients with pulmonary congestion at baseline but an EF of 0.40 or more, suggesting a unique association between diltiazem-related late CHF and systolic LVD.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“as diltiazem and verapamil can have negative inotropic effects in patients with LVEF < 40%.222,534,535”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [535]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Research works printed but not linked: 14
- Hossack KF, Pool PE, Steel P, Crawford MH, DeMaria AN, Cohen LS, Ports TA: Efficacy of diltiazem in angina on effort: A multicenter trial. Am J Cardiol 1982;49:567-572
- Strauss WE, McIntyre KM, Parisi AF, Shapiro W: Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: Report of a cooperative clinical trial. Am J Cardiol 1982;49:560-566
- Pepine CJ, Feldman RL, Hill JA, Conti CR, Mehta J, Hill C, Scott E: Clinical outcome after treatment of rest angina with calcium blockers: Comparative experience during the initial year of therapy with diltiazem, nifedipine, and verapamil. Am Heart J 1983;106:1341-1347
- Boden WE, Bough EW, Reichman MJ, Rich VB, Young PM, Korr KS, Schulman RS: Beneficial effects of high-dose dil- tiazem in patients with persistent effort angina on p-blockers and nitrates: A randomized, double-blind, placebo-controlled cross-over study. Circulation 1985;71:1197-1205
- Porter CB, Walsh RA, Badke FR, O'Rourke RA: Differential effects of diltiazem and nitroprusside on left ventricular function in experimental chronic volume overload. Circulation 1983;68:685-692
- Murakami T, Hess OM, Krayenbuehl HP: Left ventricular function before and after diltiazem in patients with coronary artery disease. JAm Coll Cardiol 1985;5:723-730
- The Multicenter Diltiazem Postinfarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-392
- Greenberg H, Gillespie J, Dwyer EM Jr, the Multicenter Post-Infarction Research Group: A new electrocardiographic classification for post-myocardial infarction clinical trials. Am J Cardiol 1987;59:1057-1063
- Kaplan EL, Meier P: Nonparametric estimation from incom- plete observations. JAm Stat Assoc 1958;53:457-481
- Marcus FI, Friday K, McCans J, Moon T, Hahn E, Cobb L, Edwards J, Kuller L: Age-related prognosis after acute myo- cardial infarction (the Multicenter Diltiazem Post-Infarction Trial). Am J Cardiol 1990;65:559-566
- Chadda K, Goldstein S, Byington R, Curb JD: Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-510
- Packer M, Gottlieb SS, Kessler PD: Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure. The basis of a new physiologic approach to control of arrhythmia. Am J Med 1986;80:23-29
- Packer M, Meller J, Medina N, Yushak M, Smith H, Holt J, Guererro J, Todd GD, McAllister RG Jr, Gorlin R: Hemody- namic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation 1982;65:660-668
- Joshi PI, Dalal JJ, Ruttlet MSJ, Sheridan DJ, Henderson AH: Nifedipine and left ventricular function in beta-blocked patients. Br Heart J 1981;45:457-459
Cited by
Sorted by citations
Items 501–525 of 525
Jaski, B. E. (2000) · Developments in cardiovascular medicine · doi:10.1007/978-1-4615-4379-4_11
Cardiac Disease in Older Adults
Aronow, W. S., & Frishman, W. H. (2020) · Springer eBooks · doi:10.1007/978-3-319-47771-8_15
Pharmacologic Management of Atrial Fibrillation and Flutter
Saluja, D. S., Hickey, K. T., & Reiffel, J. A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-41967-7_16
Cheema, A., & Calkins, H. G. (2006) · Fundamental and clinical cardiology · doi:10.3109/9781420020168.010
Systems Analysis of Cardiac B-Adrenergic Signaling Regulation
Yang, J. H. (2012) · doi:10.18130/v33n5p
The Role of Neurohormonal Antagonists in Hibernating Myocardium
Lahiri, A., Senior, R., & Khattar, R. (1999) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199900003-00002
(2004) · CRC Press eBooks · doi:10.1201/b14847-9
Second generation dihydropyridine calcium channel blockers for heart failure
van Marum, R. J., Zwinderman, A. A., & Cleophas, A. J. M. (2002) · doi:10.1002/14651858.cd003835
Section 13: Evaluation and Therapy for Heart Failure in the Setting of Ischemic Heart Disease
(2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2010.05.022
β-adrenoceptor antagonists and antianginal drugs
Maggioni, A. P., Franzosi, M. G., & Latini, R. (1992) · Side effects of drugs annual · doi:10.1016/s0378-6080(05)80499-4
Calcium Antagonists (Calcium Channel Blockers)
(2007) · Humana Press eBooks · doi:10.1007/978-1-59745-238-0_5
Management of Overt Heart Failure
Hauptman, P. J., & Swedberg, K. B. (2009) · Wiley eBooks · doi:10.1002/9781444309768.ch47
Miller, R. J. H., & Howlett, J. G. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3080
Yаkushin, S. S., & Pereverzeva, K. G. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-5562
Duttaroy, A. K., & Mallick, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99570-2.00019-9
(2000) · Time to knit · doi:10.1016/s1166-4568(19)30091-9
Antiarrhythmic Drug Therapy for Acute Management of Atrial Fibrillation and Atrial Flutter
Habibi, M., Rahim, M. A., & Mittal, S. (2025) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2025.10.003
Use of Antioxidants in Patients with Congestive Heart Failure
Ducharme, A., Rouleau, J. L., & White, M. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-387-29553-4_19
Hemodynamic and Cardiac Effects of Nisoldipine in Ischemic Left Ventricular Dysfunction
Rousseau, M. F. (1999) · Springer eBooks · doi:10.1007/978-3-642-60220-7_4
Atrial Fibrillation Risk Management and Emerging Therapies
Vaughan, M., Khetarpal, B. K., & Mehta, N. K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124612
“CCBs in these patients are to be avoided, as diltiazem has been demonstrated to significantly increase HF progression [79] (Figure 3). https://doi.org/10.3390/jcm15124612”
InfluentialTailoring Cardiac Therapy for the Elderly
Urthaler, F. (1999) · Cardiovascular Medicine · doi:10.3390/cardiovascmed2010003
Vieira, J. L., & Montenegro, C. E. L. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20260195i
“8 Although contextualized in the post-infarction period and not in isolated AF, these data support the precautionary principle when negative inotropism exists in vulnerable ventricles.”
Diretriz Brasileira de Insuficiência Cardíaca – 2026
Simões, M. V., Moura, L. Z., Martins, S. M., Mourilhe‐Rocha, R., Danzmann, L. C., Neto, J. A. D. F., Marcondes‐Braga, F. G., de Oliveira, M. T., de Albuquerque, D. C., Freitas, A. F., et al. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20260830
Klinik und Symptomatologie der chronischen Herzinsuffizienz
Böhm, M., & Erdmann, E. (2000) · Springer eBooks · doi:10.1007/978-3-662-12156-6_30
第3回 心不全の病態と治療研究会「循環制御からみた心不全の病態」
Konstam, M. A. (1996) · 心臓 · doi:10.11281/shinzo1969.28.supplement2_32
Metadata
- Authors
- Goldstein, R. E., Boccuzzi, S. J., Cruess, D., & Nattel, S.
- Affiliations
- Uniformed Services University of the Health Sciences (US)
- Venue
- Circulation
- Published
- 1991-01
- Volume
- 83
- Issue
- 1
- Pages
- 52-60
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2090674352
- Cited by
- 521
- References
- 0
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 14 · 2023: 16 · 2022: 16 · 2021: 7 · 2020: 24 · 2019: 13 · 2018: 15 · 2017: 17 · 2016: 15 · 2015: 17 · 2014: 4 · 2013: 16 · 2012: 11
- FWCI
- 17.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Henry M. Jackson Foundation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- diltiazem, congestive heart failure, myocardial infarction, left ventricular dysfunction, ejection fraction, calcium channel blockers, pulmonary congestion, adverse drug reactions
- MeSH terms
- Diltiazem, Double-Blind Method, Follow-Up Studies, Heart Failure, Humans, Myocardial Infarction, Stroke Volume, Life Tables, Ventricular Function, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
